Literature DB >> 18049093

Reduced thalamic 18F-flurodeoxyglucose retention in adults with neurofibromatosis type 1.

Ralph Buchert1, Daniel von Borczyskowski, Florian Wilke, Michael Gronowsky, Reinhard E Friedrich, Winfried Brenner, Janos Mester, Malte Clausen, Victor F Mautner.   

Abstract

OBJECTIVE: Neurofibromatosis type1 (NF1) is associated with cognitive and motor deficits whose pathogenesis is not well understood. 18F-Flurodeoxyglucose positron emission tomography (FDG PET) might be used to investigate putative functional correlates in the brain.
METHODS: Whole-body FDG PET including the brain had been performed in 29 NF1 patients suspected for malignant peripheral nerve sheath tumours (20 females, nine males, age 31.2+/-11.8 years). Twenty-nine age-matched and sex-matched subjects without evidence of neurological/psychiatric disease in whom FDG PET had been performed for NF1-unrelated oncological indication served as controls. Individual brain FDG retention images were stereotactically normalized and scaled to a common median retention value within the brain. Scaled FDG retention was compared between the NF1 group and the control group on a voxel-by-voxel base using ANCOVA in SPM2 with the FDG uptake period as covariate. The corrected significance level alpha=0.05 was used. Voxel-based analysis was complemented by volume of interest (VOI)-based analysis using predefined standard VOIs.
RESULTS: The voxel-based group comparison revealed a significant reduction of scaled FDG retention in the thalamus of the NF1 subjects within a cluster of 11.6 ml. There were no further significant effects, neither hypo-retention nor hyper-retention. Reduction of relative FDG retention in the thalamus in the NF1 subjects was confirmed by VOI analysis. The magnitude of the reduction was about 8%.
CONCLUSIONS: The thalamus appears to be affected in adults with NF1. The observed magnitude of the reduction of scaled thalamic FDG retention in adults is smaller than previously reported in children. This may be consistent with a stabilization of the disease process with age.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18049093     DOI: 10.1097/MNM.0b013e3282f1bbf5

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  6 in total

1.  Perfusion single photon emission computed tomography in a mouse model of neurofibromatosis type 1: towards a biomarker of neurologic deficits.

Authors:  Ivayla Apostolova; Dagmara Niedzielska; Thorsten Derlin; Eva J Koziolek; Holger Amthauer; Benedikt Salmen; Jens Pahnke; Winfried Brenner; Victor F Mautner; Ralph Buchert
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-18       Impact factor: 6.200

2.  Reduced cerebral arterial spin-labeled perfusion in children with neurofibromatosis type 1.

Authors:  K W Yeom; R M Lober; P D Barnes; C J Campen
Journal:  AJNR Am J Neuroradiol       Date:  2013-06-13       Impact factor: 3.825

3.  GABA deficiency in NF1: A multimodal [11C]-flumazenil and spectroscopy study.

Authors:  Inês R Violante; Miguel Patricio; Inês Bernardino; José Rebola; Antero J Abrunhosa; Nuno Ferreira; Miguel Castelo-Branco
Journal:  Neurology       Date:  2016-07-29       Impact factor: 9.910

Review 4.  Skeletal muscle and motor deficits in Neurofibromatosis Type 1.

Authors:  M A Summers; K G Quinlan; J M Payne; D G Little; K N North; A Schindeler
Journal:  J Musculoskelet Neuronal Interact       Date:  2015-06       Impact factor: 2.041

5.  Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.

Authors:  Manuel Schütze; Danielle de Souza Costa; Jonas Jardim de Paula; Leandro Fernandes Malloy-Diniz; Carlos Malamut; Marcelo Mamede; Débora Marques de Miranda; Michael Brammer; Marco Aurélio Romano-Silva
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

6.  Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA).

Authors:  Stavros Stivaros; Shruti Garg; Jonathan Green; Maria Tziraki; Ying Cai; Owen Thomas; Joseph Mellor; Andrew A Morris; Carly Jim; Karolina Szumanska-Ryt; Laura M Parkes; Hamied A Haroon; Daniela Montaldi; Nicholas Webb; John Keane; Francisco X Castellanos; Alcino J Silva; Sue Huson; Stephen Williams; D Gareth Evans; Richard Emsley
Journal:  Mol Autism       Date:  2018-02-22       Impact factor: 7.509

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.